Cheapest GLP-1 in 2026: $50–$699 Cost Paths Compared

The short price answer

Searching for the **cheapest GLP-1** usually produces numbers that are not directly comparable. One page may show an insured copay. Another may advertise only an introductory dose. A telehealth program may quote a care fee without medication. A compounded product may sit beside an FDA-approved medicine even though the FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. [S9]

This guide uses a narrower method. We checked current FDA prescribing information, official manufacturer self-pay pages, and the Centers for Medicare & Medicaid Services on August 3, 2026. We compare FDA-approved weight-management products and official access paths only. We do not rank telehealth providers, recommend a medicine, or treat a starting price as a long-term price.

Every product compared here is a prescription-only medicine: none of these prices is available without a valid prescription from a licensed clinician, and the manufacturer program, plan, or pharmacy must also accept it. [S2] [S4] [S6]

The lowest official number we verified is the **$50 copay** under the Medicare GLP-1 Bridge. It is not available to everyone. CMS describes it as a temporary program for eligible Medicare Part D beneficiaries, running from July 1, 2026, through December 31, 2027. The drugs must be prescribed for weight management, and the eligible list currently includes Foundayo, Wegovy tablets and injection, and Zepbound KwikPen. [S7] [S8]

For self-pay access outside that program, current official pages show **$149 starting prices** for Wegovy tablets and Foundayo. Those headline prices are attached to starting or early strengths. The current FDA labels identify Wegovy 25 mg as the tablet maintenance dose, while Foundayo begins at 0.8 mg and may move through higher strengths based on response and tolerability. [S1] [S2] [S3] [S4]

At the labeled maintenance level, the lowest official self-pay amount we verified is $299 per month. Intermediate titration strengths can cost less: LillyDirect lists Foundayo 2.5 mg at $199 per 30-day month. NovoCare lists Wegovy 25 mg tablets at $299 per month. LillyDirect lists Foundayo 5.5 mg and 9 mg at $299, and 14.5 mg and 17.2 mg at $299 when the refill-timing condition is met. Those are prices, not treatment recommendations; a prescriber determines whether a product and labeled strength are appropriate. [S1] [S3] [S4]

The table answers the literal price question while preserving the qualifiers. It does not prove which medicine will cost least for one person. Insurance benefits, program eligibility, prescription decisions, refill timing, needles, clinician fees, laboratory charges, and shipping can change the actual total.

What “cheapest” must include

A useful comparison needs one consistent unit. We use the official page's defined month or supply period, identify the strength tied to each number, and separate five payment lanes:

That last lane is where many “from” prices break. A medication price is not automatically a telehealth program total. Before comparing providers, use our full GLP-1 program cost method and line-by-line provider fee worksheet. They handle the costs this product-level guide intentionally does not rank.

We include a number only when an official current source states the amount and its key qualifier. We attach the number to a specific product, formulation, strength, and access program. We do not convert a starting offer into an annual average. We do not assume a higher strength will be prescribed. We do not subtract a coupon without documented eligibility. We mark compounded products as a separate regulatory lane rather than using them to declare a winner.

The result is deliberately less dramatic than an affiliate leaderboard. It is also more useful: the lowest visible number appears beside the condition that makes it true.

1. **Medicare Bridge copay.** A narrow federal demonstration with eligibility and clinical criteria, not an ordinary retail cash price. [S7] [S8]
2. **Manufacturer self-pay price.** A price offered under manufacturer terms, often outside insurance and subject to change. [S1] [S3] [S5]
3. **Introductory price.** A number limited to a starting strength, new patient, first fills, or expiration date. [S1] [S3] [S5]
4. **Later-dose or maintenance price.** The amount attached to a strength used after initiation or identified in the label as maintenance. [S1] [S2] [S3] [S4] [S5] [S6]
5. **Total program cost.** Medication plus care, membership, labs, supplies, shipping, and other required charges.

Wegovy official self-pay prices

Wegovy is a GLP-1 receptor agonist. Its current FDA label indicates WEGOVY tablets, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight and at least one weight-related comorbid condition; the label also covers WEGOVY injection, whose adult weight-reduction maintenance dosages are 1.7 mg or 2.4 mg, with 2.4 mg recommended. [S2]

For tablets, the FDA label identifies **1.5 mg once daily as the starting dosage** and **25 mg once daily as the maintenance dosage**. The label also lists 4 mg and 9 mg tablet strengths. [S2]

That makes “Wegovy for $149” true but incomplete. The $149 figure belongs to 1.5 mg and a time-limited 4 mg offer. It should not be described as the continuing price for the 25 mg maintenance strength. [S1] [S2]

For injection, NovoCare lists $199 per month for patients new to the Wegovy Savings Offer and NovoCare Pharmacy at 0.25 mg and 0.5 mg, for the first two monthly fills through December 31, 2026. Its price guide then lists $349 per month for the 0.25 mg through 2.4 mg strengths and $399 for Wegovy HD 7.2 mg. The FDA label identifies 1.7 mg or 2.4 mg as adult weight-reduction maintenance strengths, with 2.4 mg recommended. [S1] [S2]

Novo Nordisk states that eligibility and restrictions apply and reserves the right to modify or cancel the program. A month for the injection offer is one box of four pens. Those conditions belong next to the price, not in invisible fine print. [S1]

Foundayo official self-pay prices

Foundayo contains orforglipron and is an oral GLP-1 receptor agonist. The current FDA label indicates it for long-term weight reduction in adults with obesity, or adults with overweight and at least one weight-related comorbid condition, with a reduced-calorie diet and increased physical activity. [S4]

The label starts at 0.8 mg once daily, moves to 2.5 mg after at least 30 days, then to 5.5 mg after at least another 30 days. It allows later increases to 9 mg, 14.5 mg, or 17.2 mg based on treatment response and tolerability. This is label context, not a self-directed instruction; medication changes belong with the prescriber. [S4]

Foundayo shows why a starting price and a later-treatment price must be separated. The $149 headline is tied to the 0.8 mg starting strength. The verified later strengths begin at $199 for 2.5 mg and reach $299 from 5.5 mg upward. The two highest listed strengths keep the $299 amount only when the Journey Program refill timing is met. [S3] [S4]

Lilly states that eligibility is required, savings are subject to monthly and annual limits, the program is not insurance, and terms may be changed or ended. The manufacturer defines a month as 30 days on this page. [S3]

Zepbound official self-pay prices

Zepbound contains tirzepatide, a GIP and GLP-1 receptor agonist. Its current FDA label indicates it for long-term weight reduction in adults with obesity, or adults with overweight and at least one weight-related comorbid condition, with a reduced-calorie diet and increased physical activity. [S6]

The label identifies 2.5 mg once weekly for four weeks as the starting dosage. For weight reduction and long-term maintenance, it lists 5 mg, 10 mg, or 15 mg once weekly. LillyDirect separately states that 2.5 mg is not approved as a maintenance dose. [S5] [S6]

So “Zepbound starts at $299” is accurate only when it stays attached to the 2.5 mg starting dose. The lowest listed maintenance strength is 5 mg at $399 on the page we checked. Higher listed strengths show a lower Journey Program amount when refilled within 45 days and a higher regular price when that condition is missed. [S5] [S6]

Lilly defines the program month as 28 days and one single-patient-use KwikPen. It also says a pen-needle purchase is required. Eligibility, monthly and annual limits, and changing terms apply. [S5]

The $50 Medicare GLP-1 Bridge

The Medicare GLP-1 Bridge is the lowest official out-of-pocket number in this comparison, but it is also the narrowest access path. CMS says the program runs from July 1, 2026, through December 31, 2027, for eligible Medicare Part D beneficiaries. Eligible beneficiaries have a $50 copay. [S7]

CMS currently lists these products when used for weight management:

The program operates outside the normal Part D coverage and payment flow. CMS states that the Part D deductible does not apply, the $50 does not count toward true out-of-pocket costs, and the low-income subsidy is not added to that copay. [S7]

Eligibility is not established by having Part D alone. CMS's provider page sets out the clinical criteria for the Bridge, including that the drug be prescribed for weight management and used with current and ongoing lifestyle modification including structured nutrition and physical activity consistent with the FDA-approved label; a clinician and the program determine whether the criteria are met. [S8]

For a reader who may qualify, the accurate next step is to check the current CMS criteria and work through the prescription and program-eligibility process. It is not accurate to advertise “GLP-1s cost $50 with Medicare” without the Part D, product, indication, clinical-criteria, and program-period boundaries.

• Foundayo in its covered formulations. [S8]
• Wegovy injection and tablets. [S8]
• Zepbound KwikPen; CMS excludes Zepbound single-dose vials and single-dose pens from the Bridge. [S8]

Insurance and total monthly cost

Insurance can produce a lower or higher out-of-pocket amount than self-pay, but a public article cannot calculate one person's benefit. Coverage depends on the product, indication, plan, formulary, prior authorization, deductible, pharmacy, and fill. Insurance support from a clinic is an administrative service, not proof of coverage; see our insurance support versus coverage guide.

Use this formula before comparing any advertised program:

**Monthly total = medication + care or membership + required labs + supplies + shipping + insurance cost sharing + other mandatory fees.**

Then attach these qualifiers:

Our online GLP-1 program cost comparison tracks provider-level offers, while the GLP-1 cost calculator helps keep unlike billing periods from being compared as if they were the same. This article stays focused on current official product and access-path evidence.

• Amount due today.
• Number of fills or months covered.
• Strength or formulation tied to the amount.
• New-patient or refill-timing requirement.
• Whether insurance is used or bypassed.
• Whether spending counts toward a deductible or out-of-pocket maximum.
• Whether a clinician visit, lab panel, needle, or shipping charge is separate.
• What happens when the introductory period ends.

Why compounded prices stay separate

Top-ranking pages for this query include affiliate provider rankings that list compounded products beside FDA-approved medicines. We do not use those amounts to declare the cheapest FDA-approved GLP-1.

FDA states that unapproved versions do not undergo its review for safety, effectiveness, and quality before marketing. It also states that compounded drugs are not FDA approved and should be used only when a patient's medical needs cannot be met by an FDA-approved drug. [S9]

FDA reports adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide products; it also notes that injectable GLP-1 drugs require refrigeration as indicated in their package inserts and urges consumers buying medicine online to purchase only from state-licensed pharmacies. [S9]

That does not mean every compounded prescription is unlawful or that a general article can decide what one patient needs. It means the comparison must preserve the regulatory difference. A compounded-product quote belongs in a separate conversation with the prescriber and pharmacy, not in a table that implies equivalence to Foundayo, Wegovy, or Zepbound.

A safe comparison checklist

Use this sequence to turn a low headline number into a comparable quote:

This checklist does not choose a medicine. It makes the cost question precise enough for a clinician, insurer, manufacturer program, and pharmacy to answer without mixing different products or billing lanes.

1. **Confirm the treatment lane.** Is the number for an FDA-approved weight-management product, an off-label product, or a compounded drug? Do not merge those categories. [S2] [S4] [S6] [S9]
2. **Confirm the formulation.** Tablet, single-dose pen, vial, and KwikPen can have different prices and program rules. [S1] [S5] [S8]
3. **Confirm the strength.** Ask whether the advertised price belongs only to initiation or also applies at the labeled later or maintenance strength. [S1] [S2] [S3] [S4] [S5] [S6]
4. **Confirm the supply period.** NovoCare defines a month for the Wegovy injection offer as one box of four pens, the Zepbound program month is 28 days and one single-patient-use KwikPen, and the Foundayo page defines a 30-day month. [S1] [S3] [S5]
5. **Confirm eligibility.** Self-pay, commercial insurance, and Medicare Bridge are different rails. A valid prescription or plan membership does not by itself prove program acceptance. [S3] [S5] [S7] [S8]
6. **Confirm the post-offer price.** Record the date or fill when the price changes and the amount that replaces it. [S1] [S3] [S5]
7. **Add required fees.** Include care, membership, labs, supplies, needles, shipping, and pharmacy charges.
8. **Save the source and date.** Prices and program rules are volatile. A screenshot without a date and terms is not durable evidence.

Update policy

Prices and program rules were checked on **August 3, 2026**. We will recheck this guide when:

If an official source stops stating a price or qualifier, we will mark it **not stated** rather than carry the old number forward. Verify current details with the manufacturer program, insurer or CMS, pharmacy, and prescribing clinician before acting.

If Zepbound is the product being priced, verify the current 2026 Zepbound coupon terms.

• the Wegovy 4 mg offer reaches its stated August 31, 2026 change date; [S1]
• the Wegovy injection new-patient offer reaches its stated December 31, 2026 boundary; [S1]
• CMS changes the Bridge drug list, criteria, copay, accounting, or December 31, 2027 end date; [S7] [S8]
• FDA changes a cited label or the compounded-drug guidance; [S2] [S4] [S6] [S9]
• LillyDirect changes a Foundayo or Zepbound price, refill window, or regular-price term. [S3] [S5]